Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?

TY - JOUR

T1 - Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?

AU - Rendl, Gundula

AU - Schweighofer-Zwink, Gregor

AU - Sorko, Stefan

AU - Gallowitsch, Hans-Jürgen

AU - Hitzl, Wolfgang

AU - Reisinger, Diana

AU - Pirich, Christian

N1 - Hitzl: Research and Innovation Management, Biostatistics and Publication of Clinical Trial Studies, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Department of Ophthalmology and Optometry, University Hospital Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Research Program Experimental Ophthalmology and Glaucoma Research, University Hospital Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria; Pirich, Rendl, Schweighofer-Zwink: Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, Austria

PY - 2022

Y1 - 2022

KW - TYROSINE KINASE INHIBITORS

KW - EMISSION-TOMOGRAPHY

KW - PROGNOSTIC VALUE

KW - SOLID TUMORS

KW - DOUBLE-BLIND

KW - METASTASES

KW - PARAMETERS

KW - MANAGEMENT

KW - SORAFENIB

KW - CARCINOMA

U2 - 10.3390/cancers14081868

DO - 10.3390/cancers14081868

M3 - Original Article

C2 - 35454777

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 8

ER -